Why IMU is a multi multi bagger, page-26085

Lifestar,

I can’t see the local punters getting a look in here.

Thats why PH has been in the US with LC regularly. They won’t raise capital until ONCARLYTICS data is released.

Being an open Label Trial they know exactly what’s happening. LC has made several comments about sophisticated US investors being very interested in ONCARLYTICS. As did one of the other Senior Executives (memory fail here ).

and further when asked if she thought raising further capital would be difficult LC replied “ no, not I don’t ecpect any difficulty “

It’s worth remembering the CEO and Chair are working well fwd of where our attention is focussed.

When they raise capital , they will also have a detailed plan and costings , of how they will spend the money..

In the webinar presentation they highlighted 2”Ph2” trials. Vaxinia and Azer-Cel. And then we’ve got expansion trials across several platforms. including Oncarlytics/Azer-Cel and quite possibly Removo Pancreatic Cancer trials.

This company is about to grow in a very big way. This will require big funds. So O would expect to see a cap raise from US institutions. And quite possibly a Nasdaq Listing.

With the Azer-Cel results being so good, if Vaxinia and Oncarlytics are of a similar standard , we won’t get a look in. It will be oversubscribed and at a much higher price than .05,

Last years Cap Raise was land Azer-Cel. Which has been show now as a masterstroke. This next move comes with a lot of meticulous planning and great clinical results in hand.